Logo image of MTL

MECHEL PJSC-SPONSORED ADR (MTL) Stock Fundamental Analysis

NYSE:MTL - New York Stock Exchange, Inc. - US5838406081 - ADR - Currency: USD

2.25  -0.05 (-2.17%)

After market: 2.25 0 (0%)

Fundamental Rating

1

Taking everything into account, MTL scores 1 out of 10 in our fundamental rating. MTL was compared to 151 industry peers in the Metals & Mining industry. MTL may be in some trouble as it scores bad on both profitability and health. MTL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MTL was profitable.
MTL Yearly Net Income VS EBIT VS OCF VS FCFMTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 50B -50B -100B

1.2 Ratios

Industry RankSector Rank
ROA 31.85%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTL Yearly ROA, ROE, ROICMTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 -10 -20 -30

1.3 Margins

Industry RankSector Rank
OM 22.61%
PM (TTM) 19.51%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTL Yearly Profit, Operating, Gross MarginsMTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 20 -20 40 -40

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for MTL has been reduced compared to 1 year ago.
MTL has a worse debt/assets ratio than last year.
MTL Yearly Shares OutstandingMTL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 100M 200M 300M 400M
MTL Yearly Total Debt VS Total AssetsMTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 100B 200B 300B 400B

2.2 Solvency

MTL has an Altman-Z score of 0.04. This is a bad value and indicates that MTL is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of -0.02 indicates that MTL is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -0.02
Debt/FCF N/A
Altman-Z 0.04
ROIC/WACCN/A
WACCN/A
MTL Yearly LT Debt VS Equity VS FCFMTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 -100B -200B

2.3 Liquidity

A Current Ratio of 0.26 indicates that MTL may have some problems paying its short term obligations.
MTL has a Quick Ratio of 0.26. This is a bad value and indicates that MTL is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.11
MTL Yearly Current Assets VS Current LiabilitesMTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 100B 200B 300B 400B 500B

More info and screens

3

3. Growth

3.1 Past

MTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 386.40%, which is quite impressive.
Measured over the past years, MTL shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -41.84% on average per year.
MTL shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.22%.
Measured over the past years, MTL shows a small growth in Revenue. The Revenue has been growing by 0.95% on average per year.
EPS 1Y (TTM)386.4%
EPS 3Y-58.68%
EPS 5Y-41.84%
EPS Q2Q%184.7%
Revenue 1Y (TTM)36.22%
Revenue growth 3Y-3.9%
Revenue growth 5Y0.95%
Sales Q2Q%59.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTL Yearly Revenue VS EstimatesMTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 100B 200B 300B
MTL Yearly EPS VS EstimatesMTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 1.07, the valuation of MTL can be described as very cheap.
The average S&P500 Price/Earnings ratio is at 29.63. MTL is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 1.07
Fwd PE N/A
MTL Price Earnings VS Forward Price EarningsMTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.96
MTL Per share dataMTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MTL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MECHEL PJSC-SPONSORED ADR

NYSE:MTL (2/25/2022, 8:04:00 PM)

After market: 2.25 0 (0%)

2.25

-0.05 (-2.17%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/bmo
Inst Owners0%
Inst Owner Change-65.09%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap910.75M
Analysts44
Price Target0.13 (-94.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1.07
Fwd PE N/A
P/S 0.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 3.96
EPS(TTM)2.1
EY93.33%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS10.69
BVpS-5.74
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 31.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 22.61%
PM (TTM) 19.51%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover1.63
Health
Industry RankSector Rank
Debt/Equity -0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.11
Altman-Z 0.04
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)386.4%
EPS 3Y-58.68%
EPS 5Y-41.84%
EPS Q2Q%184.7%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)36.22%
Revenue growth 3Y-3.9%
Revenue growth 5Y0.95%
Sales Q2Q%59.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A